Volition announced a collaboration with Sysmex to optimize its circulating nucleosome-based Nu.Q NETs H3.1 assay on the Sysmex system. The test quantifies neutrophil extracellular traps (NETs) via H3.1-nucleosomes in plasma, with elevated levels associated with illness severity. Volition said the companies previously worked to transfer the assay to Sysmex analyzers, and will now further optimize performance for diseases connected to NETosis, including the broader clinical area around inflammation and infection. The agreement’s financial terms were not disclosed. From a commercialization standpoint, integrating into a large diagnostics platform can speed adoption and support consistent lab workflows—key for a biomarker that may be used for both clinical decision-making and monitoring.